Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September
Precision BioSciences (Nasdaq: DTIL) announced its participation in three upcoming investor conferences, showcasing its ARCUS® genome editing platform.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision BioSciences (Nasdaq: DTIL) announced its participation in three upcoming investor conferences, showcasing its ARCUS® genome editing platform. The schedule includes the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 12:40 PM ET, the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, at 1:30 PM ET, and the Morgan Stanley Global Healthcare Conference on September 17, 2020, at 8:45 AM ET. Live webcasts will be available on the company’s website, with replays accessible for 30 days.
Details
News Market Reaction – DTIL
The recorded move for DTIL in the trading session of this news was +0.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced its participation in the following upcoming investor conferences:
- 2020 Wells Fargo Virtual Healthcare Conference
Date: Thursday, September 10, 2020
Time: 12:40 – 1:10 PM ET
- H.C. Wainwright Annual Global Investment Conference
Date: Monday, September 14, 2020
Time: 1:30 – 1:50 PM ET
- Morgan Stanley Global Healthcare Conference
Date: Thursday, September 17, 2020
Time: 8:45 – 9:15 AM ET
Live webcasts of each presentation will be accessible on the Company’s website, www.PrecisionBiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. Elo Life Systems is a wholly-owned subsidiary of Precision BioSciences also using ARCUS to benefit human health and wellness with novel food products that enhance the nutrition and diversity of global food supply. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.messier@precisionbiosciences.com
Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.